Wells Fargo
AVTX icon

Wells Fargo’s Avalo Therapeutics AVTX Stock Holding History

Wells Fargo’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,100
Closed -$778K – 7296
2026
Q1 		$778K Buy
+52,100
New +$815K ﹤0.01% 3886

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo's AVTX Position: Q2 2026 in Review

Wells Fargo opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 36,576 shares worth $676K. The stake represents ﹤0.01% of the portfolio and ranks #4397 among its holdings. This is a return to the name: Wells Fargo previously reported a position in AVTX as recently as Q3 2024.

Wells Fargo first reported a position in AVTX in Q2 2019 and has held it in 22 quarters since. The position peaked at $853K in Q2 2019. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Wells Fargo held 36,576 shares of Avalo Therapeutics worth $676K as of Q2 2026.
  • Avalo Therapeutics was a new Wells Fargo position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4397 holding.
  • Wells Fargo first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • Wells Fargo's Avalo Therapeutics position peaked at $853K in Q2 2019.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.